Haleon (HLN) 21st Annual dbAccess Global Consumer Conference 2024 summary
Event summary combining transcript, slides, and related documents.
21st Annual dbAccess Global Consumer Conference 2024 summary
1 Feb, 2026Regional overview and growth strategy
EMEA and LATAM represent 44% of the global population and account for 40% of company revenues, with GBP 4.5 billion in annual sales across 100+ markets and a workforce of 12,000 employees.
The region is organized into seven business units, supported by 13 integrated factories, with LATAM fully supplied internally.
Growth is driven by a balanced portfolio: one-third of revenues from oral health, nearly a quarter from pain relief, and strong positions in respiratory health and VMS.
Power brands account for 68% of regional revenue, complemented by local growth brands with strong heritage in specific markets.
Organic revenue growth in EMEA & LATAM reached 12.6% in 2023, supported by net revenue management and operational efficiencies.
Brand and category performance
Leading positions in pain relief (Panadol, Voltaren), oral health (Sensodyne, Parodontax), and VMS (Centrum), with double-digit growth in key brands.
Parodontax achieved double-digit growth over three years, with 20% growth in Q1, driven by expert engagement and expanded access.
Panadol delivered double-digit growth, offering solutions across all life stages and reinforcing trust during the COVID period.
Centrum expanded in emerging markets through geo-expansion, increased activation, and tailored products for low-income consumers, achieving market leadership in Brazil and launches in Egypt.
Local brands like Be-Total (Italy) and Grand-Pa (South Africa) maintain strong consumer loyalty and market leadership.
Go-to-market and channel strategy
Pharmacy is the dominant channel, accounting for over 60% of revenues and nearly double the size of the next competitor.
Mass market represents over 30% of revenues, with top-tier supplier status in more than 60% of markets.
Digital commerce is under 10% of revenues, limited by regulatory and digital maturity differences across countries.
Shopper Science Lab and advanced analytics optimize category growth and shopper experience in both pharmacy and mass market channels.
Pharmacist engagement and education are key, with 80% of pharmacist recommendations leading to purchases.
Latest events from Haleon
- Gross margin rose 220 bps as profit and shareholder returns grew, despite U.S. and cold/flu softness.HLN
H2 2025 (Q&A)25 Feb 2026 - 3% organic growth, 10.5% profit growth, and strong shareholder returns in 2025.HLN
H2 202525 Feb 2026 - Q3 organic revenue up 6.1%, profit up 7.4%, with margin expansion and FY 2024 guidance reaffirmed.HLN
Q3 2024 TU3 Feb 2026 - Oral health and emerging markets offset U.S. softness as savings and innovation drive growth.HLN
Barclays 18th Annual Global Consumer Staples Conference 20253 Feb 2026 - Strong H1 organic growth, margin expansion, and cash flow support upgraded FY outlook.HLN
H1 2024 (Q&A)2 Feb 2026 - Strong organic growth, margin expansion, and robust shareholder returns in 2024.HLN
H2 202430 Jan 2026 - Sustained growth, margin gains, and innovation drive strong performance and strategic flexibility.HLN
17th Annual Global Consumer Staples Conference 202422 Jan 2026 - Growth targets of 4-6% are supported by innovation, divestments, and global expansion.HLN
Bernstein's 21st Pan European Annual Strategic Decisions Conference20 Jan 2026 - Purposeful, data-driven marketing and innovation fuel growth, trust, and brand differentiation.HLN
Fireside Chat19 Jan 2026